Higashiyama M, Doi O, Kodama K, Yokouchi H, Inaji H, Nakamori S, Tateishi R
Department of Thoracic Surgery, Centre for Adult Diseases, Osaka, Japan.
Eur J Cancer. 1994;30A(6):792-7. doi: 10.1016/0959-8049(94)90294-1.
In the present study, pS2 protein expression in pulmonary adenocarcinoma was investigated on paraffin-embedded sections obtained from 170 patients. 28 (16%) patients showed varying degrees of pS2 protein expression in the cytoplasm of tumour cells, as detected by immunohistochemical staining with anti-pS2 protein antibody. There was a significant association between pS2 protein expression and larger tumour size, and the acinar or bronchiolo-alveolar subtype. However, no significant correlations between pS2 protein status and the other clinicopathological factors, i.e. T-factor, N-factor, stage and histological differentiation, were shown. In contrast to breast cancer, patients with pS2-positive pulmonary adenocarcinomas had a significantly worse prognosis than those with pS2-negative pulmonary adenocarcinomas; this was true for stage I patients, as well as for all patients. Multivariate analysis showed that pS2 protein expression was a discriminating variable in overall survival. These findings suggest that pS2 protein status is a possible prognostic indicator in pulmonary adenocarcinoma.
在本研究中，我们对170例患者石蜡包埋切片中的肺腺癌pS2蛋白表达情况进行了研究。通过抗pS2蛋白抗体免疫组化染色检测发现，28例（16%）患者的肿瘤细胞胞质中呈现不同程度的pS2蛋白表达。pS2蛋白表达与肿瘤体积较大以及腺泡或细支气管肺泡亚型之间存在显著关联。然而，未显示pS2蛋白状态与其他临床病理因素（即T因子、N因子、分期和组织学分化）之间存在显著相关性。与乳腺癌不同，pS2阳性肺腺癌患者的预后明显差于pS2阴性肺腺癌患者；I期患者以及所有患者均如此。多因素分析表明，pS2蛋白表达是总生存期的一个鉴别变量。这些发现提示，pS2蛋白状态可能是肺腺癌的一个预后指标。
